Kelvin Bryan Tan (Kelvin B Tan)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

End Stage Renal Disease

Antiplatelet Therapy

St Segment Elevation Myocardial Infarction

Top Venues

Clinical drug investigation

Health systems and reform

Drug and alcohol review

Expert review of pharmacoeconomics & outcomes research

Ministry of Health Singaore

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Ministry of Health Singaore Oct 01 2012

Singapore

Director :: Policy Research and Evaluation

Publications

Lee Seng Esmond Seow, Jue Hua Lau, Edimansyah Abdin, Swapna K Verma, Kelvin Bryan Tan, Mythily Subramaniam
Mapping the Schizophrenia Quality of Life Scale to EQ-5D, HUI3 and SF-6D utility scores in patients with schizophrenia. Expert review of pharmacoeconomics & outcomes research (2023)
Zhenghong Liu, Desmond Ren-Hao Mao, Stephanie Fook-Chong, Charles Chia Meng Mak, Xi Xiang Esther Tan, Jun Tian Wu, Kelvin Bryan Tan, Marcus Eng-Hock Ong, Fahad J Siddiqui
Nationwide Alcohol-related visits In Singapore's Emergency departments (NAISE): A retrospective population-level study from 2007 to 2016. Drug and alcohol review 41 (5) (2022)
Edimansyah Abdin, Siow Ann Chong, Vithiya Ragu, Janhavi Ajit Vaingankar, Saleha Shafie, Swapna Verma, Ganga Ganesan, Kelvin Bryan Tan, Derrick Heng, Subramaniam Mythily
The economic burden of mental disorders among adults in Singapore: evidence from the 2016 Singapore Mental Health Study. Journal of mental health (Abingdon, England) (2021)
Kelvin Bryan Tan, Chien Earn Lee
Integration of Primary Care with Hospital Services for Sustainable Universal Health Coverage in Singapore. Health systems and reform 5 (1) (2020)
Kaavya Narasimhalu, Yoong Kwei Ang, Doreen Su Yin Tan, Deidre Anne De Silva, Kelvin Bryan Tan
Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations. Clinical drug investigation 40 (11) (2020)